Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer In Year-End Drug-Licensing Push

by Rick Mullin
January 3, 2011 | A version of this story appeared in Volume 89, Issue 1

San Diego-based Lpath has granted Pfizer an exclusive option to license iSONEP, a monoclonal antibody being evaluated for the treatment of ophthalmology disorders, including wet age-related macular degeneration. Pfizer will pay Lpath $14 million and share the cost of iSONEP’s Phase I and II clinical trials. Lpath is eligible for milestone payments of as much as $497.5 million. Pfizer has also entered an agreement with Australia’s Phylogica to discover peptide-based vaccines using Phylogica’s peptide drug discovery platform. Pfizer will pay $500,000 up front and could make clinical and other milestone payments of as much as $134 million.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.